


Anti-S1PR3 Recombinant Antibody Products

Anti-S1PR3 Products
-
- Species Reactivity: Human
- Type: Mouse antibody
- Application: WB
- Mouse Anti-S1PR3 Recombinant Antibody (clone 7H9F11) (HPAB-0437-WJ)
-
- Species Reactivity: Human
- Type: Mouse IgG
- Application: ELISA, ICC
- Human Anti-S1PR3 Recombinant Antibody (clone AS55) (VS-0624-FY30)
-
- Species Reactivity: Human
- Type: Human IgG
- Application: ELISA
- Mouse Anti-S1PR3 Recombinant Antibody (clone 7H9F11); Fab Fragment (HPAB-0437-WJ-F(E))
-
- Species Reactivity: Human
- Type: Mouse Fab
- Application: ELISA, ICC
- Mouse Anti-S1PR3 Recombinant Antibody (clone 7H9F11); scFv Fragment (HPAB-0437-WJ-S(P))
-
- Species Reactivity: Human
- Type: Mouse scFv
- Application: ELISA, ICC
-
- Derivation: Phage display library screening
- Species Reactivity: Human
- Type: IgG
- Application: WB
- Rabbit Anti-S1PR3 Recombinant Antibody (VS13-YC1032) (VS13-YC1032)
-
- Species Reactivity: Human, Mouse, Rat
- Type: Rabbit IgG
- Application: WB
-
- Species Reactivity: Human
- Target: S1PR3
- Host Animal: Mouse
- Application: ELISA, FC, Cell-uptake
- Anti-S1PR3 Immunohistochemistry Kit (VS-0525-XY6328)
-
- Species Reactivity: Human
- Target: S1PR3
- Application: IHC
Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Given its significant role in regulating immune responses, S1PR3 presents a promising therapeutic target for immune-related disorders. Creative Biolabs offers a diverse collection of recombinant anti-S1PR3 antibodies, expertly engineered using our advanced technology to ensure high specificity and reactivity, thereby accelerating the development of novel therapeutic strategies.
S1PR3: A Promising Target for Cancer Immunotherapy
S1P's interaction with S1PR3 primarily drives tumor development through activation of PI3K, MAPK, and PLC pathways. Interestingly, S1PR3 appears to dampen the immune response by encouraging tumor blood vessel formation and shifting macrophages to an immunosuppressive state. Furthermore, S1P-S1PR3 signaling might contribute to a tumor-promoting inflammatory milieu by influencing cytokine release within the tumor microenvironment. Despite these complexities, the multifaceted role of S1PR3 makes it a compelling focus for the design of novel cancer immunotherapies.
Alternative Names
Sphingosine-1-phosphate receptor 3; S1P receptor 3; S1PR3; EDG-3; EDG3; LPB3; S1P3.
Background
This gene encodes a member of the EDG family of receptors, which are G protein-coupled receptors. This protein has been identified as a functional receptor for sphingosine 1-phosphate and likely contributes to the regulation of angiogenesis and vascular endothelial cell function.
FDA approved drug targets, G-protein coupled receptors
Intracellular, Membrane (different isoforms)
Cell type enhanced (Theca cells, Sertoli cells, Endometrial stromal cells, Smooth muscle cells)
Immune cell enriched (classical monocyte)
Cell line enhanced (AF22, ASC diff, ASC TERT1)
G-protein coupled receptor, Receptor, Transducer [Q99500]
Anti-S1PR3 rAb Products
Creative Biolabs provides high-quality recombinant anti-S1PR3 antibodies developed using cutting-edge technology, assuring consistency and specificity for study. These valuable tools allow scientists to thoroughly investigate S1PR3's expression, function, and signaling in various models. By targeting S1PR3, these antibodies help researchers understand its role in processes like immune cell movement and blood vessel function, thus improving our understanding of this receptor in different diseases.
Table 1. Featured anti-S1PR3 recombinant antibody products at Creative Biolabs.
Cat. No. | Product Name | Target Species | Host Species | Applications |
HPAB-0437-WJ | Mouse Anti-S1PR3 Recombinant Antibody (clone 7H9F11) | Human | Mouse IgG | ELISA, ICC |
HPAB-0437-WJ-F(E) | Mouse Anti-S1PR3 Recombinant Antibody (clone 7H9F11); Fab Fragment | Human | Mouse Fab | ELISA, ICC |
HPAB-0437-WJ-S(P) | Mouse Anti-S1PR3 Recombinant Antibody (clone 7H9F11); scFv Fragment | Human | Mouse scFv | ELISA, ICC |
MOB-1777MZ | Recombinant Mouse Anti-Human S1PR3 Antibody (clone BT72) | Human | Mouse antibody | WB |
VS-0624-FY30 | Human Anti-S1PR3 Recombinant Antibody (clone AS55) | Human | Human IgG | ELISA |
Creative Quality Control
Creative Biolabs ensures the high quality of the anti-S1PR3 recombinant antibodies through rigorous quality control. Each batch undergoes thorough testing, including SDS-PAGE, WB, ELISA, and other assays, to confirm consistent purity, specific binding to the S1PR3 target, and minimal off-target interactions. This comprehensive validation process provides researchers with dependable and reproducible antibodies, crucial for reliable S1PR3 signaling research.
Customer Reviews

Recombinant Anti-S1PR3 Vesicular Antibody, EV Displayed (VS-0425-YC566) (CAT#: VS-0425-YC566)

Recombinant Mouse Anti-Human S1PR3 Antibody (clone BT72) (CAT#: MOB-1777MZ)

Mouse Anti-S1PR3 Recombinant Antibody (clone 7H9F11); Fab Fragment (CAT#: HPAB-0437-WJ-F(E))
rAb Production
Unlock the potential of your S1PR3 research with Creative Biolabs' premium recombinant antibodies. Engineered with cutting-edge technology and rigorously validated, our antibodies provide a consistent and high-quality foundation for exploring the complexities of S1PR3 signaling and driving scientific discovery.
Featured Anti-xx Recombinant Antibody Production Platforms
Fig.1 Milligram-scale anti-S1PR3 recombinant antibody production.
Fig.2 Gram-scale anti-S1PR3 recombinant antibody production.
rAb Modalities
Researchers globally rely on Creative Biolabs for exceptional, custom-designed recombinant anti-S1PR3 antibodies, meticulously crafted to address their unique experimental requirements.
Fig.3 Full-length anti-S1PR3 recombinant antibody production and modalities.
S1PR-Targeted Drug Information-1
Table 2. Public drug targeting S1PR.
Company | Research phase | Classification | Condition |
ALS Therapy Development Inst (ALS TDI) (ALS Therapy Development Institute) ALS Therapy Development Institute First Affiliated Hosp Fujian Med Univ Indiana University Mitsubishi Tanabe Pharma (Originator) Novartis Taito (Originator) |
Launched - 2010 | Prodrugs |
Amyotrophic lateral sclerosis Asthma Chronic inflammatory demyelinating polyneuropathy Immunosuppression Multiple sclerosis Multiple sclerosis, primary progressive Multiple sclerosis, relapsing-remitting Optic neuritis Polyneuropathy, demyelinating Renal Disorders Rett syndrome Schizophrenia Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) Transplant rejection Transplant rejection, kidney |
Lpath (Originator) Lpath Therapeutics (Lpath) Merck Serono Pfizer |
Phase II |
Cancer Immunotherapy Humanized Monoclonal Antibodies |
Cancer Cancer, kidney (renal cell carcinoma) Heart failure Retinal detachment Wet macular degeneration (exudative) |
VYNE Therapeutics (Originator) | Phase I/II |
Fixed-Dose Combinations Prodrugs |
Atopic dermatitis |
Institute of Materia Medica of Beijing (Originator) | Phase I | Prodrugs | Psoriasis |
Washington University (Originator) | Phase I |
Carbon-Radiolabeled Products Nuclear Imaging Agents |
Atherosclerosis Injury, vascular Multiple sclerosis Neurodegeneration Neuroinflammation |
Bristol-Myers Squibb (Originator) | Phase I | Prodrugs |
Autoimmune disease Rheumatoid arthritis |
Daiichi Sankyo (Originator) | Discontinued | Prodrugs |
Immunological Disorders Multiple sclerosis |
Washington University (Originator) | Preclinical |
Fluorine-Radiolabeled Products Nuclear Imaging Agents |
Neuroinflammation |
Capital Medical University (CMU) (Originator) Ocean University of China (Originator) |
Preclinical | Chemosensitizers | Cancer, colorectal |
Washington University (Originator) | Preclinical |
Fluorine-Radiolabeled Products Nuclear Imaging Agents |
Neurological Disorders |
Washington University (Originator) | Preclinical |
Fluorine-Radiolabeled Products Nuclear Imaging Agents |
Neurological Disorders |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
S1PR-Targeted Drug Information-2
Table 3. Drug targeting S1PR (under development).
Company | Research phase | Classification | Condition |
Autobahn Therapeutics (Originator) | Biological Testing | Prodrugs |
Adrenoleukodystrophy, X-linked Multiple sclerosis |
Autobahn Therapeutics (Originator) | Biological Testing | Prodrugs |
Adrenoleukodystrophy, X-linked Multiple sclerosis |
Novartis (Originator) | Biological Testing | Deuterated Compounds | Inflammation, lung |
Korea Institute of Science & Technology (Originator) | Biological Testing | Selenium Compounds | Multiple sclerosis |
Korea Institute of Science & Technology (Originator) | Biological Testing |
Prodrugs Selenium Compounds |
Multiple sclerosis |
Korea Institute of Science & Technology (Originator) | Biological Testing | Selenium Compounds | Multiple sclerosis |
Beijing Shenlantai Pharmaceutical Technology (Originator) | Biological Testing | Chemosensitizers | Cancer |
University of California (Originator) | Biological Testing |
Pegylated Drugs Prodrugs |
Cancer Multiple sclerosis |
Celgene | Biological Testing | Cocrystals |
Multiple sclerosis Psoriasis |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
With a strong foundation in antibody engineering and manufacturing, Creative Biolabs delivers high-quality S1PR3 recombinant antibodies, designed for consistent and exceptional performance across various research applications. Understanding the critical importance of S1PR3 in your investigations, we are dedicated to providing antibodies that adhere to the highest standards of reliability. Researchers delving into the complexities of S1PR3 are invited to contact us for customized pricing that suits their unique research requirements.